FDA Approves Bristol Myers Squibb's Breyanzi for Relapsed or Refractory Marginal Zone Lymphoma

Reuters12-05
FDA Approves Bristol Myers Squibb's Breyanzi for Relapsed or Refractory Marginal Zone Lymphoma

The FDA has approved Bristol Myers Squibb's Breyanzi (lisocabtagene maraleucel) for the treatment of relapsed or refractory marginal zone lymphoma, marking its approval in a fifth cancer type. Breyanzi is now the first and only CAR T cell therapy authorized for this patient population, further solidifying its position as the leading CD19-directed CAR T cell therapy for the broadest range of B-cell malignancies.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Bristol-Myers Squibb Company published the original content used to generate this news brief via Business Wire (Ref. ID: 20251203055321) on December 05, 2025, and is solely responsible for the information contained therein.
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Comments

We need your insight to fill this gap
Leave a comment